Post Conference Report

ISPE European Drug Utilisation Research Group
(EuroDURG) Conference 2017

Patients, Medicines, Bytes: Drug Utilisation Research
and E-health

Wednesday, 15th – Friday, 17th November 2017
Technology & Innovation Centre, University of Strathclyde,
Glasgow

From
Björn Wettermark – EuroDURG Chair
Katja Taxis - Scientific Committee Chair
Marion Bennie – Local Organising Committee Chair
TABLE OF CONTENTS

SECTION 1 CONFERENCE PREPARATION AND PARTICIPANT STATISTICS .............................................. 5

1. Organising Committees ...................................................................................................................... 5
2. Registration Statistics .......................................................................................................................... 5
3. Function Statistics ............................................................................................................................... 6
4. Delegate Badge and Bag ...................................................................................................................... 7
5. Exhibition/Sponsorship ......................................................................................................................... 7
6. Marketing/Promotion ............................................................................................................................. 8
7. Abstracts ............................................................................................................................................... 8
8. Speakers ............................................................................................................................................... 8

SECTION 2 - CONFERENCE PROGRAM ................................................................................................. 8

9. Programme Overview ........................................................................................................................... 10
10. EuroDURG Best Poster Awards 2017 ............................................................................................... 12
11. Conference in Action ........................................................................................................................... 13

SECTION 3 - CONFERENCE PARTICIPANT EVALUATION .................................................................... 14

12. General comments on the conference: ............................................................................................. 16
Executive Summary

In November 2017, EuroDURG, the European chapter of ISPE special interest group for Drug Utilization Research, welcomed 264 delegates who travelled from 39 countries (Europe, North America, South America, Africa, Asia, Australia) to our 3-day meeting entitled: Patients, Medicines, Bytes: Drug Utilization Research and E-health, held in Glasgow, Scotland at the University of Strathclyde. Our ambition was to challenge ourselves as a community to embrace the rapidly expanding digitalization of our health and social care systems as an opportunity to build on our existing strengths in population level drug utilization and clinical outcomes research. The increase in individualized data streams (from sensors, patient reported outcomes, etc.) presents the potential to expand our understanding of the public value and safety of established and new medicines. However, to do so we need to expand our data science teams and methodological approaches to manage and interpret these rapidly expanding data flows in a responsive manner to drive advancements in patient care.

The conference speakers (over 40 invited speakers) rose to the challenge. This was centred around three key plenary sessions: firstly, a journey into the future digital world from an industry expert - Gillian Docherty – Chief Executive of Datalab Innovation Centre, Scotland focused on bringing new digital advancements into the public sector in Scotland, followed by Björn Wettermark contextualizing this from a DUR perspective; secondly, a challenge from Andrew Morris – Director of the new Health Data Research UK Institute – to maximize the connectivity and intelligence generation capability arising from “Big Data”, and the need to expand the diversity of our multi-disciplinary team expertise and do research at scale across boundaries, followed by Sarah Cunningham-Burley – Professor of Medical and Family Sociology, Genetic and Population Health Sciences, University of Edinburgh - outlining best practice in how to assure the patient and public voice is integrated within our research; and thirdly, our own three musketeers - Katja Taxis, Lisa Pont and Veronika Wirtz presenting the global perspective on DUR and health policy – a fitting international perspective to close the conference.

Our plenary sessions were complimented by an extensive program of introductory and advanced education sessions, led by international experts, to kick of the conference on Wednesday morning followed by a mix of interspersed parallel sessions, workshops and mini-symposiums focused on DUR methods, clinical topics, health policy and patient perspectives. Our delegates were active throughout, with 54 oral abstract presentations across the sessions and a further 146 posters, all of whom were part of a poster walk over 2 days to stimulate discussion on the wealth of research ongoing within the community.

The scientific programme was accompanied by a EuroDURG social programme to promote networking, old and new, across the 3 days. We started with a Welcome Reception, hosted by the City of Glasgow, in the historic Glasgow City Chambers built in 1888, accompanied by a Scottish bagpipe welcome. Our Gala dinner was hosted along the Clyde riverfront at the Glasgow Science Centre which involved a traditional Scottish ceilidh.

The conference evaluation questionnaire was completed by 139 of the participants. Of these, 54% worked in academia, 25% in health care and the remaining in various other areas including health authorities or insurances. About 40% had been to previous EuroDURG meetings. Respondents were
very positive about the conference. The overall scientific content was rated with a 4.3 (out of 5, being the best mark), relevance to work was rated as 4.2, social programme 4.3, networking opportunities 4.2 and respondents were also happy about the practical arrangements rating this as 4.3. The majority of individual educational and scientific sessions were also rated very highly above 4. Finally, 99% of respondents wrote they would attend another EuroDURG meeting.

Marion Bennie
Chair, Local Organising Committee

Katja Taxis
Chair, Scientific Committee

Björn Wettermark
EuroDURG Chair
SECTION 1 CONFERENCE PREPARATION AND PARTICIPANT STATISTICS

1. Organising Committees

The Local Organising Committee comprised individuals from the Scientific Committee, the host (the University of Strathclyde) and from Abbey Conference & Events. Due to the global make-up of the committee, the team met both in person and virtually over the 12 months prior to the conference. Two planning meetings took place in Glasgow, where the team travelled across the city to select then view the conference and social event spaces and discuss the logistics of the event itself.

LOCAL ORGANISING COMMITTEE

Marion Bennie (Chair)¹
Samantha Alvarez Madrazo¹
Emma Dunlop Corcoran¹
Monique Elseviers
Anja Fischer²
Brian Godman¹
Amanj Kurdi¹
Ellie Quinn¹
Katja Taxis

¹University of Strathclyde
²Abbey Conference & Events

SCIENTIFIC COMMITTEE

Katja Taxis, The Netherlands (Chair)
Marion Bennie, UK
Anna Birna Almarsdottir, Denmark
Ria Benko, Hungary
Matt-Mouley Bouamrane, UK
Monique Elseviers, Belgium
Brian Godman, UK / Sweden
Jolanta Gulbonovic, Lithuania
Simon Hurding, UK
Janet Krksa, UK
Paraskevi Voula Papaioannidou, Greece
Elisabetta Poluzzi, Italy
Lisa Pont, Australia
Jane Robertson, WHO
Margaret Ryan, UK
Gabriel Sanfélix-Gimeno, Spain
Gisbert W. Selke, Germany
Catherina Sermet, France
Fatima Suleman, South Africa
Robert Vander Stichele, Belgium
Björn Wettermark, Sweden
Veronika Wirtz, USA

2. Registration Statistics

264 Delegates travelled from over 39 countries to be part of the EuroDURG 2017 conference.
3. Function Statistics

Welcome Reception

A Welcome Reception took place in Glasgow City Chambers on Wednesday 15th November from 7-8pm hosted by the Lord Provost’s Office, City of Glasgow. Drinks were sponsored by the city of Glasgow and canapes were served. Counsellor Bailie Ade Aibinu extended delegates a warm welcome to the City in his address, and provided an interesting and entertaining history of the City of Glasgow. A total of 195 people attended.

Gala Dinner

The Gala Dinner took place on Thursday 16th November in the Science Centre, Glasgow. The ticket was included in the delegate fee and 184 delegates confirmed their attendance. A ceilidh band played after dinner.
4. Delegate Badge and Bag

**Delegate Packs**

A cotton bag containing a copy of the conference programme, flyers, a pen, delegate list, map and Glasgow tourist material (provided by the City of Glasgow) were handed out to all delegates at registration.

**Delegate Badge**

There were different types of name badges:

- Day Registrations
- Full Conference
- Committee Member
- Speaker
- Staff

5. Exhibition/Sponsorship

There were 3 exhibitors in total: Farr Scotland; NHS National Services Scotland; and the University of Strathclyde. The exhibition consisted of a table top and chairs in the foyer area where all catering breaks and lunch were served. This worked very well as it allowed total exposure for each exhibitor, and the length of the breaks also allowed ample time for delegates to visit each stand. EuroDURG also had a table and advertised a book and the EuroDURG declaration there.
6. Marketing/Promotion

Numerous e-zines were sent out to the conference database throughout the year, including:

- Save-the-Date in November 2016
- Registration and Abstract Submission Open in December 2016
- Abstract Submission Deadline in March 2017 x 2
- Abstract Submission Deadline in April 2017 (only one week to go)
- Abstract Submission Deadline extended in April 2017
- “Scientific Programme now available” in July 2017
- “One day fees available” in August 2017
- Confirmed speakers and programme in August 2017
- “Four weeks left to register” in October 2017
- Online registration closing / info on Glasgow in November 2017

E-zines were distributed to the main database, and the Conference website was updated regularly.

7. Abstracts

A total of 214 abstracts were received via the conference website managed by Abbey Conference and Events team. A full review process was undertaken by the EuroDURG Executive Committee supported by an extended cohort of reviewers. A total of 146 posters were accepted and poster sessions took place in the afternoons of Thursday 16th and Friday 17th November. A further 54 abstracts were accepted as oral presentations. A few late cancellations (14 abstracts) were not presented.

8. Speakers

There were more than 40 speakers. The budget allowed for 2 nights’ accommodation and travel costs for up to £400 in total.

SECTION 2 - CONFERENCE PROGRAM

The conference was centred around three key plenary sessions: firstly, a journey into the future digital world from an industry expert - Gillian Docherty – Chief Executive of Datalab Innovation Centre, Scotland focused on bringing new digital advancements into the public sector in Scotland, followed by Björn Wettermark contextualizing this from a DUR perspective; secondly, a challenge from Andrew Morris – Director of the new Health Data Research UK Institute – to maximize the connectivity and intelligence generation capability arising from “Big Data”, and the need to expand the diversity of our multi-disciplinary team expertise and do research at scale across boundaries, followed by Sarah Cunningham-Burley - Professor of Medical and Family Sociology, Genetic and Population Health Sciences, University of Edinburgh - outlining best practice in how to assure the
patient and public voice is integrated within our research; and thirdly, our own three musketeers - Katja Taxis, Lisa Pont and Veronika Wirtz presenting the global perspective on DUR and health policy – a fitting international perspective to close the conference. The full conference programme book and abstract book are available through the EuroDURG conference website (http://eurodurg2017.net/ open until November 2018).

Our plenary sessions were complimented by an extensive program of introductory and advanced education sessions, led by international experts, to kick off the conference on Wednesday morning followed by a mix of interspersed parallel sessions, workshops and mini-symposiums focused on DUR methods, clinical topics, health policy and patients. Our delegates were active throughout, with 54 oral abstract presentations across the sessions and a further 146 posters, all of whom were part of a themed poster walk (Antibiotics; Cardiovascular; Cancer / Biologics; Drug Policy; Elderly; Nervous System; Diabetes / Adherence; Interventions / Pregnancy / Paediatrics; and Surprising Others) over 2 days to stimulate discussion on the wealth of research ongoing within the community.

Each poster presentation comprised of 3 minutes followed by 2 minutes of discussion. The chair and co-chair for each poster walk elected the best poster based on scientific content, the quality of the poster and the way the results were presented and defended. Each winner received an e-copy of the DURbook: Drug Utilization Research: Methods and Applications.

At the conclusion of the conference delegates were asked: “What are the three topics you will work on after the EuroDURG 2017 conference.” A digital application, accessible through delegates’ phones, generated an instant Word Cloud at the meeting (see below). The Programme at a Glance is detailed overleaf.
## Programme Overview

### Wednesday

<table>
<thead>
<tr>
<th>Time</th>
<th>Main Auditorium B</th>
<th>Main Auditorium C</th>
<th>Rooms 6 &amp; 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 10:30</td>
<td>E1W</td>
<td>E2W</td>
<td>E3W</td>
</tr>
<tr>
<td></td>
<td>CNC of Drug Utilization</td>
<td>Time Series Analysis</td>
<td>Data Sources – Validation Research</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td>E4W</td>
<td>E5W</td>
<td>E6W</td>
</tr>
<tr>
<td></td>
<td>Adherence Research Using Databases</td>
<td>Quality of Quality Indicators</td>
<td>Using Field Studies in DUR</td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Scientific Programme Part I**

- Welcome & Keynote Lectures
  - K1W Digital - The Future is Here, Gillian Docherty
  - K2W Digitalizing and DUR: Challenges and Opportunities, Bjorn Wettermark
- 15:00 – 16:00: Coffee Break
- 16:00 – 17:30: P1W, Antimicrobial Use and Resistance; P2W, ePrescribing and eDispensing Systems; P3W, Adherence
- 19:00: Welcome Reception: City Chambers, Glasgow

### Thursday

<table>
<thead>
<tr>
<th>Time</th>
<th>Main Auditorium B</th>
<th>Main Auditorium C</th>
<th>Rooms 6 &amp; 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 10:00</td>
<td>P4T</td>
<td>P5T</td>
<td>P6T</td>
</tr>
<tr>
<td></td>
<td>Prescribing and de-Prescribing in Old Age</td>
<td>Gender Difference and Safety in DUR</td>
<td>Decision Support to Improve Drug Use</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 12:00</td>
<td>P7T</td>
<td>P8T</td>
<td>P9T</td>
</tr>
<tr>
<td></td>
<td>Globalization of DUR</td>
<td>Drug Use in Pregnancy and Pediatrics</td>
<td>Evolving Methods in DUR</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Scientific Programme Part II**

- W1T, DUR on the Life Cycle of Drugs
- S2T, Data Visualization
- W3T, From Intervention to Implementation
- 14:30 – 16:00: Coffee Break/14:45 Poster Walk
- 16:00 – 17:30: Keynote Lectures
  - K3T Taking a "Molecule to Man" Approach, Andrew Morris
  - K4T The Patient and Public Voice – Using Big Data for Public Benefit, Sarah Cunningham-Burley
- 17:30 – 18:30: EuroDURG General Assembly
- 19:30: EuroDURG Networking Dinner: Glasgow Science Centre
<table>
<thead>
<tr>
<th>FRIDAY</th>
<th>MAIN AUDITORIUM B</th>
<th>MAIN AUDITORIUM C</th>
<th>ROOMS 6 &amp; 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 10:00</td>
<td><strong>P10F</strong> Inform and Evaluate Health Policy</td>
<td><strong>P11F</strong> Citizen Science and DUR</td>
<td><strong>P12F</strong> Cardiovascular Therapy</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td><em>Coffee Break</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 12:00</td>
<td><strong>P13F</strong> Patient Reported Outcome Measures</td>
<td><strong>P14F</strong> New Medicines: Management of Innovations</td>
<td><strong>P15F</strong> DUR Across the World</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td><em>Lunch Break</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC PROGRAMME PART V</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td><strong>S4F</strong> Predictive Analytics, Patient Level Drug Exposure</td>
<td><strong>W5F</strong> Role of DUR in Comparative Effectiveness Research</td>
<td><strong>W6F</strong> Cross-National Comparison Guideline and Checklist</td>
</tr>
<tr>
<td>14:30 – 16:00</td>
<td><em>Coffee Break / 14:45 Poster Walk</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 – 17:30</td>
<td><em>Keynote Lecture</em> <strong>K5F</strong> Drug Utilization and Health Policy from a Global Perspective, Katja Taxis, Veronika Wirtz, Lisa Pont</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Closing Ceremony**

*E = Educational Session  
K = Keynote Lecture  
P = Parallel Session  
S = Symposium  
W = Workshop*
# EuroDURG Best Poster Awards 2017

<table>
<thead>
<tr>
<th>POSTER CATEGORY</th>
<th>BEST POSTER WINNER</th>
<th>AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics / Other</td>
<td>Joanna Johnson</td>
<td>NHS Glasgow, UK</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Tanja Mueller</td>
<td>University of Strathclyde, UK</td>
</tr>
<tr>
<td>Cancer / Biologics</td>
<td>Ylena Ingrasciotta</td>
<td>University of Messina, IT</td>
</tr>
<tr>
<td>Drug Policy</td>
<td>Augusto Guerra Jr</td>
<td>University of Minas Gerais, BR</td>
</tr>
<tr>
<td>Elderly</td>
<td>Gary O Brien</td>
<td>University College Cork, IR</td>
</tr>
<tr>
<td>Nervous system</td>
<td>Sandy Maumus-Robert</td>
<td>University of Bordeaux, FR</td>
</tr>
<tr>
<td>Diabetes / Adherence</td>
<td>Linda Van Eikenvorst</td>
<td>University of Groningen, NL</td>
</tr>
<tr>
<td>Interventions / Pregnancy / Paediatrics</td>
<td>Anne Benard-Larièbre</td>
<td>University of Bordeaux, FR</td>
</tr>
<tr>
<td>Surprising others</td>
<td>Catharina Schuiling</td>
<td>University of Groningen, NL</td>
</tr>
</tbody>
</table>

![Award ceremony photos]
11. Conference in Action
SECTION 3 - CONFERENCE PARTICIPANT EVALUATION

The conference evaluation questionnaire was completed by 139 of the participants. Of these, 54% worked in academia, 25% in health care and the remaining in various other areas including health authorities or insurances. About 40% had been to previous EuroDURG / ISPE meetings. Respondents were very positive about the conference. The overall scientific content, relevance to work, social programme, networking opportunities and the practical arrangements were all rated on average between 4.2 and 4.5 out of 5 (Figure 1). Finally, 99% of respondents wrote they would attend another EuroDURG meeting.

Figure 1: EuroDURG 2017 Survey Response - Overall Conference Rating

How do you rate the following from 1 (very poor) to 5 (excellent)?

- Practical arrangements (facilities, information, materials) 4.3
- Value of the meeting for networking and establishing new contacts 4.2
- Social programme (dinner, reception) 4.3
- Relevance of the conference for your work 4.2
- Overall scientific content of the meeting 4.3
Are there any potential topics you would like to discuss in future conferences?

“Maybe a workshop or couple of lectures about research methods based on databases would be useful.”

“Emerging medicines safety information.”

“EuroDURG is very educational which is a good thing. But sometimes one has to decide whether certain topics/elements should be either scientific or educational. Some workshops, or part of them, assumed that you are an active scientist, while other elements were more aimed at an educational direction. The mix in the conference is good but maybe a clearer distinction between the two aspects would benefit a future meeting.”

“Cardiovascular disease, adherence and HRQOL.”

“Maybe some more about how to involve patients in drug utilization research, for example in intervention studies. How can patients be stimulated to use their drugs in the correct way?”

“I think it would be worthwhile to explain a little more on drug regulation, approval, reimbursement and monitoring in European/global context. Could be of interest to especially academics - perhaps as pre conference course, else on a specific topic/workshop as we did this year on PCSK-9 inhibitors - where an obvious link was made to where DU is relevant in the various stages of the drug life cycle.”

“Medicine costs and prices, prioritisation - when is a drug worth the price, decision making processes in different countries on which drugs to use, and which not to use. Policy.Biosimilar opportunities.”

“More time for challenges especially around data collection in CEE and LMIC countries where this is challenging vs. Western EU countries.”

“The Essential Medicines Concept from a global perspective (not focusing on access but on selection and policy decisions first and foremost, in face of appalling pressure for innovation adoption).”

“Measure of drug effectiveness and safety in a context of uncertainty: how do we assess the benefits and harms of treatments in patient groups that cannot participate in RCTs ?”

“Validity and reliability database in CNC studies.”
12. General comments on the conference:

“Very well organised with excellent presenters and sessions.”

“Excellent opportunity to network and establish new contacts.”

“Good source of inspiration.”

“Friendly and familial atmosphere!”

“Guidelines and check-list on: 1) measuring impact on interventions related with drug utilization; 2) quality indicators; 3) electronic prescription and dispensing systems.”

“It was great! So many nice sessions! The only disadvantage was that sometimes interesting sessions were planned in the same timeframe, which made it hard to choose.”

“Time series analysis in drug prices, database of biosimilar’s use, high drug costs and challenges in public health.”

“I very much enjoyed being with a very friendly and welcoming group of people who share some of my own research interests and who are willing to discuss new ideas.”

“It was a very informative conference, and due to the fact there are not thousands of delegates (as is the case at some other international conferences) it make it more intimate with more change to network.”

“I think all relevant topics were covered with sufficient depth - really nice range of work in posters and presentations/workshop sessions, and a lot of discussion about the impact this work can have on policy/practice.”

“Drugs and the environment´ various methods specific therapeutic areas and their challenges, the frontier in science of DUR.”

“A political detailing - the Method as practiced in Australia and USA/Canada/ Norway.”

“Problem related malaria and tuberculosis should be part of discussion after those are serious problem after some drugs are resistance and many people died of those .”

“Pediatric DU Persistence methods in respiratory medicine.”

“Possibilities and limiting factors of DUR research across Europe and around the world.”

“Congratulations to the organizing team. It was a great conference with high quality presentations. In particular, it was nice to have 30 minutes breaks between session blocks and 1 hour lunch breaks to meet with colleagues. I liked the poster walks and the opportunity for younger researchers to present their work.”

“Excellent organization. Everyone was made to feel welcome.”

“Very well organised with excellent presenters and sessions.”

“Excellent opportunity to network and establish new contacts.”

“Good source of inspiration.”

“Friendly and familial atmosphere!”

“Guidelines and check-list on: 1) measuring impact on interventions related with drug utilization; 2) quality indicators; 3) electronic prescription and dispensing systems.”

“It was great! So many nice sessions! The only disadvantage was that sometimes interesting sessions were planned in the same timeframe, which made it hard to choose.”

“Time series analysis in drug prices, database of biosimilar’s use, high drug costs and challenges in public health.”

“I very much enjoyed being with a very friendly and welcoming group of people who share some of my own research interests and who are willing to discuss new ideas.”

“It was a very informative conference, and due to the fact there are not thousands of delegates (as is the case at some other international conferences) it make it more intimate with more change to network.”

“I think all relevant topics were covered with sufficient depth - really nice range of work in posters and presentations/workshop sessions, and a lot of discussion about the impact this work can have on policy/practice.”

“Drugs and the environment´ various methods specific therapeutic areas and their challenges, the frontier in science of DUR.”

“A political detailing - the Method as practiced in Australia and USA/Canada/ Norway.”

“Problem related malaria and tuberculosis should be part of discussion after those are serious problem after some drugs are resistance and many people died of those .”

“Pediatric DU Persistence methods in respiratory medicine.”

“Possibilities and limiting factors of DUR research across Europe and around the world.”

“Congratulations to the organizing team. It was a great conference with high quality presentations. In particular, it was nice to have 30 minutes breaks between session blocks and 1 hour lunch breaks to meet with colleagues. I liked the poster walks and the opportunity for younger researchers to present their work.”

“Excellent organization. Everyone was made to feel welcome.”